Andrew C James1, Franklin C Lee2, Jason P Izard2, William P Harris3, Heather H Cheng3, Song Zhao4, John L Gore2, Daniel W Lin2, Michael P Porter2, Evan Y Yu3, Jonathan L Wright2. 1. Department of Urology, University of Washington School of Medicine, Seattle, WA. Electronic address: acjames@uw.edu. 2. Department of Urology, University of Washington School of Medicine, Seattle, WA. 3. Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.
Abstract
INTRODUCTION/ BACKGROUND: The aim of this study was to examine whether TUR of all visible endophytic tumors performed before RC, with or without NC, affects final pathologic staging. PATIENTS AND METHODS: We retrospectively reviewed data from patients with clinical T2-T4N0-1 urothelial carcinoma of the bladder who underwent RC at our institution between July 2005 and November 2011. Degree of TUR was derived from review of operative reports. We used multivariate logistic regression to assess the association of maximal TUR on pT0 status at time of RC. RESULTS: Of 165 eligible RC patients, 81 received NC. Reported TUR of all visible tumors was performed in 38% of patients who did not receive NC and 48% of NC patients (P = .19). Nine percent of patients who underwent maximal TUR and did not receive NC were pT0, whereas among NC patients, pT0 was seen in 39% and 19% of those with and without maximal TUR, respectively (P = .05). On multivariate analysis in all patients, maximal TUR was associated with a nonsignificant increased likelihood of pT0 status (odds ratio [OR], 2.03; 95% confidence interval [CI], 0.84-4.94), which was significant when we restricted the analysis to NC patients (OR, 3.17; 95% CI, 1.02-9.83). CONCLUSION: Maximal TUR of all endophytic tumors before NC is associated with complete pathologic tumor response at RC. Candidates for NC before RC should undergo resection of all endophytic tumors when feasible. Larger series are warranted to see if maximal TUR leads to improved overall and disease-specific survival.
INTRODUCTION/ BACKGROUND: The aim of this study was to examine whether TUR of all visible endophytic tumors performed before RC, with or without NC, affects final pathologic staging. PATIENTS AND METHODS: We retrospectively reviewed data from patients with clinical T2-T4N0-1 urothelial carcinoma of the bladder who underwent RC at our institution between July 2005 and November 2011. Degree of TUR was derived from review of operative reports. We used multivariate logistic regression to assess the association of maximal TUR on pT0 status at time of RC. RESULTS: Of 165 eligible RC patients, 81 received NC. Reported TUR of all visible tumors was performed in 38% of patients who did not receive NC and 48% of NC patients (P = .19). Nine percent of patients who underwent maximal TUR and did not receive NC were pT0, whereas among NC patients, pT0 was seen in 39% and 19% of those with and without maximal TUR, respectively (P = .05). On multivariate analysis in all patients, maximal TUR was associated with a nonsignificant increased likelihood of pT0 status (odds ratio [OR], 2.03; 95% confidence interval [CI], 0.84-4.94), which was significant when we restricted the analysis to NC patients (OR, 3.17; 95% CI, 1.02-9.83). CONCLUSION: Maximal TUR of all endophytic tumors before NC is associated with complete pathologic tumor response at RC. Candidates for NC before RC should undergo resection of all endophytic tumors when feasible. Larger series are warranted to see if maximal TUR leads to improved overall and disease-specific survival.
Authors: Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf Journal: Can Urol Assoc J Date: 2019-01-31 Impact factor: 1.862
Authors: Andrew R Leone; Kamran Zargar-Shoshtari; Gregory J Diorio; Pranav Sharma; David Boulware; Scott M Gilbert; Julio M Powsang; Jingsong Zhang; Wade J Sexton; Philippe E Spiess; Michael A Poch Journal: Clin Genitourin Cancer Date: 2017-02-01 Impact factor: 2.872
Authors: William P Parker; Philip L Ho; Stephen A Boorjian; Jonathan J Melquist; Prabin Thapa; Jeffrey M Holzbeierlein; Igor Frank; Ashish M Kamat; Eugene K Lee Journal: World J Urol Date: 2016-03-04 Impact factor: 4.226
Authors: Christopher Anderson; Ryan Weber; Darshan Patel; William Lowrance; Adam Mellis; Michael Cookson; Maximilian Lang; Daniel Barocas; Sam Chang; Elizabeth Newberger; Jeffrey S Montgomery; Alon Z Weizer; Cheryl T Lee; Bruce R Kava; Max Jackson; Anoop Meraney; Daniel Sjoberg; Bernard Bochner; Guido Dalbagni; Machele Donat; Harry Herr Journal: J Urol Date: 2016-04-01 Impact factor: 7.450
Authors: David D'Andrea; Surena Matin; Peter C Black; Firas G Petros; Homayoun Zargar; Colin P Dinney; Michael S Cookson; Wassim Kassouf; Marc A Dall'Era; John S McGrath; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeffrey M Holzbeierlein; Trinity J Bivalacqua; Srikala S Sridhar; Scott North; Daniel A Barocas; Yair Lotan; Andrew J Stephenson; Bas W van Rhijn; Philippe E Spiess; Siamak Daneshmand; Shahrokh F Shariat Journal: BJU Int Date: 2020-10-14 Impact factor: 5.588